Back to today’s briefing

Story perspectives

ITM-11 Shows Promising Results for Neuroendocrine Tumors

2/3/2025

24 5

Summary

Story summary

ITM Isotope Technologies Munich SE has unveiled promising results from its Phase 3 COMPETE trial for ITM-11, a groundbreaking treatment for inoperable gastroenteropancreatic neuroendocrine tumors. With 309 patients participating worldwide, ITM-11 demonstrated a significant boost in progression-free survival over everolimus. Excitingly, further findings will be shared soon, paving the way for a potential FDA New Drug Application in 2025.

1 of 1

Story summary

ITM Isotope Technologies Munich SE has unveiled promising results from its Phase 3 COMPETE trial for ITM-11, a groundbreaking treatment for inoperable gastroenteropancreatic neuroendocrine tumors. With 309 patients participating worldwide, ITM-11 demonstrated a significant boost in progression-free survival over everolimus. Excitingly, further findings will be shared soon, paving the way for a potential FDA New Drug Application in 2025.